The effect of melatonin and atorvastatin on diabetic nephropathy
- Conditions
- Type 2 diabetes mellitus with kidney complication.Type 2 diabetes mellitus with kidney complicationsE11.2
- Registration Number
- IRCT20181118041689N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 120
Patients with type II diabetes
Diabetic patient over 40 years of age.
Patients with microalbuminuria (urinary albumin 30- 300 mg/24h)
Patients who sign a written informed consent form.
Patients with HbA1c of < 8%
Patients with blood pressure > 160 / 90 mmHg
Patients with statins intolerance.
Patients with statin-inducedmyopathy
Patients who have used immunosuppressive drugs within 3 months of the first screening visit.
Patients with intolerance to blood pressure reducing drugs (e.g., angiotensin II receptor-blocking drugs)
Patients with other illness likely to influence the trial such as congestive heart failure, hypothyroidism, severe kidney failure, polycystic kidney disease, HIV nephropathy, ischemic kidney disease, interstitial nephritis of idiopathic kidney and hepatic failure
Patients who have been kidney transplant in the past.
Patients who have taken part in other clinical trials in the last 3 months.
Patients who are pregnant or breast-feeding.
Patients who are researchers and co-workers in this trial.
Patients with a history of alcohol abuse or smoking.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rine albumin to creatinine ratio. Timepoint: Before the start of intervention and at 6 months after the start of treatment. Method of measurement: Measuring creatinine and albumin levels in urine using biochemical tests.
- Secondary Outcome Measures
Name Time Method